Article Text

other Versions

Short report
Feasibility of Chlamydia trachomatis screening and treatment in pregnant women in Lima, Peru: a prospective study in two large urban hospitals
  1. Jeanne Cabeza1,
  2. Patricia J García2,
  3. Eddy Segura1,
  4. Pedro García3,
  5. Francisco Escudero4,
  6. Sayda La Rosa2,
  7. Segundo León5,6,
  8. Jeffrey D Klausner1
  1. 1Department of Medicine/Division of Infectious Diseases, UCLA Geffen School of Medicine, Los Angeles, California, USA
  2. 2Unit of Epidemiology, STD and HIV, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru
  3. 3Instituto Nacional Materno Perinatal, Lima, Peru
  4. 4Hospital Nacional Arzobispo Loayza, Lima, Peru
  5. 5Department of Global Health, University of Washington, Seattle, Washington, USA
  6. 6Instituto de Medicina Tropical, Universidad Mayor de San Marcos, Lima, Peru
  1. Correspondence to Dr Jeanne Cabeza, Center for AIDS Research and Education (CARE), 9911 West Pico Blvd, Suite 955, Los Angeles, CA 90035, USA; jeacabez{at}


Objectives Chlamydia trachomatis, which is asymptomatic in most women, causes significant adverse effects for pregnant women and neonates. No programmes conduct antenatal screening in Latin America. We determined chlamydia prevalence, feasibility and acceptability of chlamydia screening, and adherence to treatment in pregnant women in two urban public hospitals in Lima, Peru.

Methods We offered chlamydia screening using self-collected vaginal swabs to pregnant women ≥16 years of age during their first antenatal visit. Chlamydia-infected women were contacted within 14 days and asked to bring partners for counselling and directly observed therapy with oral azithromycin. Unaccompanied women received counselling, directly observed therapy, and azithromycin to take to partners. Test of cure was performed ≥3 weeks after treatment.

Results We approached 640 women for the study and enrolled 600 (93.8%). Median age was 27.3 years (range 16–47), median lifetime partners 2.3 (range 1–50), and median gestational age 26.1 weeks (range 4–41). Chlamydia prevalence was 10% (95% CI 7.7% to 12.7%). Of 60 infected patients, 59 (98%) were treated with one dose of azithromycin. Fifty-two of 59 (88%) returned for test of cure, all of whom were treated successfully, with 46 (86%) achieving negative test of cure with one dose of azithromycin, and 6 (12%) after retreatment with a second dose.

Conclusions C. trachomatis screening and treatment in pregnancy was feasible and highly acceptable in two urban hospitals in Peru. Chlamydia prevalence was high. Clinical trials to evaluate efficacy and cost-effectiveness of chlamydia screening, and treatment of pregnant women to prevent adverse pregnancy outcomes in low-resource settings, are warranted.

  • Chlamydia Trachomatis
  • Pregnancy
  • Screening

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.